BMC recalled 20,160 sleep machines, therapy paused for some users

For your bathroom shelf and nightstand, low risk wellness tools stay outside strict device enforcement while true therapy machines still face recalls, a split confirmed when regulators restated the rule on January 6, 2026 and then listed a Class I recall of 20,160 BMC Luna G3 APAP Model LG3600 units in the United States on August 19, 2026.

You can spot the guidance by the title General Wellness: Policy for Low Risk Devices. It steps in for the 2019 guidance and covers low risk products that support a healthy lifestyle through everyday routines.

Software features meant only to maintain or encourage a healthy lifestyle without links to diagnosis, cure, mitigation, prevention or treatment fall outside the medical device definition under Section 520(o)(1)(B). Products without software and with that same purpose get enforcement discretion, which means the agency does not plan to enforce requirements under the Federal Food, Drug, and Cosmetic Act.

The policy leaves out drugs, biologics, dietary supplements, foods, cosmetics handled by other FDA Centers and combination products. Non-invasive products that estimate blood pressure for wellness purposes may fit if the planned use stays strictly tied to wellness and other terms are satisfied.

A wearable that estimates blood glucose to track nutritional effects may fit if it is specifically labeled against use by people with diabetes and pre-diabetes. A blood glucose wearable that uses minimally invasive microneedle technology does not count as low risk even when all claims stay framed around wellness.

Sensor based wellness products lose the general wellness grouping when they urge particular clinical steps, offer treatment advice, or measure for screening, diagnosis, monitoring or management of disease. They also lose that grouping when they claim to replace an FDA cleared device or when they name particular diseases or diagnostic cutoffs.

The Luna G3 APAP recall showed where the medical boundary remains in force. BMC Medical Co., Ltd. logged the recall on July 15, 2026 after identifying a firmware defect, and FDA logged Recall Number Z-2979-2026.

Firmware version G3-2.00.76 could bring up an error message and then shut down on its own and stop giving therapy during high pressure, high respiratory rate and high peak flow. BMC moved firmware to version G3-2.00.77 for 20,160 devices at the United States importers warehouse between October and December 2024, yet later found perhaps up to 196 units may have missed the upgrade. BMC had taken in no complaints or serious adverse reports as of the September 8, 2026 notice. It remains unclear whether any units without the upgrade are still in use.

Forecasts suggest steady growth on the wellness side of the divide. The North America medical wellness devices market holds a value of US$44.4 billion in 2026 and is projected to reach US$71.8 billion by 2033 at a compound annual growth rate of 7.1 percent. The United States is expected to hold 80 percent market share in 2026, while Canada is named as the fastest growing region.

Diabetic monitoring devices are forecast to hold 37 percent of revenue share in 2026, and retail sales are expected to hold over 62 percent. Consumer grade devices still raise questions over uneven readings next to hospital grade equipment, along with data privacy concerns.

Check whether 2026 retail sales meet forecasts, and how accuracy checks develop for daily trackers.